Literature DB >> 8230414

Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles.

R Kirnbauer1, J Taub, H Greenstone, R Roden, M Dürst, L Gissmann, D R Lowy, J T Schiller.   

Abstract

The L1 genes of two human papillomavirus type 16 (HPV16) isolates derived from condylomata acuminata were used to express the L1 major capsid protein in insect cells via recombinant baculoviruses. Both L1 major capsid proteins self-assembled into virus-like particles (VLP) with high efficiency and could be purified in preparative amounts on density gradients. The yield of VLP was 3 orders of magnitude higher than what has been obtained previously, using L1 derived from the prototype HPV16. DNA sequence comparison identified a single nonconserved amino acid change to be responsible for the inefficient self-assembly of the prototype L1. VLP were also obtained by expressing L1 of HPV6, HPV11, and cottontail rabbit papillomavirus, indicating that L1 from a variety of papillomaviruses has the intrinsic capacity to self-assemble into VLP. Coexpression of HPV16 L1 plus L2 by using a baculovirus double-expression vector also resulted in efficient self-assembly of VLP, and the average particle yield increased about fourfold in comparison to when L1 only was expressed. Coimmunoprecipitation of L1 and L2 and cosedimentation of the two proteins in a sucrose gradient demonstrated that L2 was incorporated into the particles. The ability to generate preparative amounts of HPV16 L1 and L1-L2 VLP may have implications for the development of a serological assay to detect anti-HPV16 virion immune responses to conformational epitopes and for immunoprophylaxis against HPV16 infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8230414      PMCID: PMC238150     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Baculovirus vectors for multiple gene expression and for occluded virus production.

Authors:  X Z Wang; B G Ooi; L K Miller
Journal:  Gene       Date:  1991-04       Impact factor: 3.688

2.  Nucleotide sequence of the HPV16 L1 open reading frame.

Authors:  A Parton
Journal:  Nucleic Acids Res       Date:  1990-06-25       Impact factor: 16.971

3.  Identification of the E5 open reading frame of human papillomavirus type 16.

Authors:  C L Halbert; D A Galloway
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

4.  Molecular cloning of viral DNA from human genital warts.

Authors:  E M de Villiers; L Gissmann; H zur Hausen
Journal:  J Virol       Date:  1981-12       Impact factor: 5.103

5.  Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11.

Authors:  N D Christensen; J W Kreider; N M Cladel; S D Patrick; P A Welsh
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

6.  Production of human papillomavirus type 16 virions in a keratinocyte cell line.

Authors:  J Sterling; M Stanley; G Gatward; T Minson
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

7.  Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts.

Authors:  S Ghim; N D Christensen; J W Kreider; A B Jenson
Journal:  Int J Cancer       Date:  1991-09-09       Impact factor: 7.396

8.  Genetic analysis of CRPV pathogenesis: the L1 open reading frame is dispensable for cellular transformation but is required for papilloma formation.

Authors:  M Nasseri; C Meyers; F O Wettstein
Journal:  Virology       Date:  1989-05       Impact factor: 3.616

9.  Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins.

Authors:  W F Jarrett; K T Smith; B W O'Neil; J M Gaukroger; L M Chandrachud; G J Grindlay; G M McGarvie; M S Campo
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

10.  Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles.

Authors:  R C Rose; W Bonnez; R C Reichman; R L Garcea
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

View more
  195 in total

1.  Role of rubella virus glycoprotein domains in assembly of virus-like particles.

Authors:  M Garbutt; L M Law; H Chan; T C Hobman
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection.

Authors:  R B Roden; P M Day; B K Bronzo; W H Yutzy; Y Yang; D R Lowy; J T Schiller
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 3.  Human papillomavirus therapy for the prevention and treatment of cervical cancer.

Authors:  Samir N Khleif
Journal:  Curr Treat Options Oncol       Date:  2003-04

4.  Expression, characterization, and immunoreactivities of a soluble hepatitis E virus putative capsid protein species expressed in insect cells.

Authors:  Y Zhang; P McAtee; P O Yarbough; A W Tam; T Fuerst
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

5.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

6.  Structural basis of oligosaccharide receptor recognition by human papillomavirus.

Authors:  Jhimli Dasgupta; Malgorzata Bienkowska-Haba; Marcos E Ortega; Hetalkumar D Patel; Sabrina Bodevin; Dorothe Spillmann; Brooke Bishop; Martin Sapp; Xiaojiang S Chen
Journal:  J Biol Chem       Date:  2010-11-29       Impact factor: 5.157

7.  Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.

Authors:  Laura M Fahey; Adam B Raff; Diane M Da Silva; W Martin Kast
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 8.  Concepts of papillomavirus entry into host cells.

Authors:  Patricia M Day; Mario Schelhaas
Journal:  Curr Opin Virol       Date:  2013-12-14       Impact factor: 7.090

9.  HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model.

Authors:  Xiaofei Yan; Depu Wang; Fengli Liang; Ling Fu; Cheng Guo
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs.

Authors:  Tilo Senger; Lysann Schädlich; Sonja Textor; Corinna Klein; Kristina M Michael; Christopher B Buck; Lutz Gissmann
Journal:  Vaccine       Date:  2009-12-08       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.